Population Pharmacokinetics of Imatinib in CML Patients in Iran
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2016
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics
- 02 Sep 2016 Planned End Date changed from 1 Jul 2014 to 1 Jul 2017.
- 02 Sep 2016 Status changed from recruiting to discontinued.
- 04 Jul 2014 New trial record